People's health is our priority
Apollo Specialty has a pipeline of high-quality biosimilar medicines to increase access to life-changing biologic therapies. Our biosimilars have the potential to improve patient access to treatment across a wide range of indications. For nearly two decades, biosimilars have been a reliable source of medicines in Europe. The first European biosimilar was approved in 2006, and since then, nearly 4.5 billion patient treatment days have been provided to European patients. Apollo intends to bring biosimilars to the European market by leveraging its parent company’s portfolio and technology.
What are biosimilars?
Biosimilars are biological medicinal products that are highly like other biological medicinal products for which the period of exclusivity has expired. They are approved to the same standards of pharmaceutical quality, safety, and efficacy as all biological medicines.